A

Amgen

Makes biotech medicines for serious illnesses

HCP Marketing Director - IgG4-RD

Full-TimeUpdated on 10/24/2026
$195.9k - $265k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, MBA, PhD
Naperville, IL, USA+6 moreMore locations: Northbrook, IL, USA | Deerfield, IL, USA | Schaumburg, IL, USA | Glenview, IL, USA | Evanston, IL, USA | Buffalo Grove, IL, USA
HybridFlex commuter / hybrid arrangement at the listed Illinois locations.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A doctorate degree and 4 years of marketing experience, or a master's degree and 7 years of marketing or commercial experience, or a bachelor's degree and 9 years of marketing or commercial experience.
  • Demonstrated success leading pharmaceutical or biotechnology product launches, including launch strategy, commercial performance management, and field readiness.
  • Experience launching first-in-class therapies or new indications and building markets in areas of high unmet need.
  • Demonstrated success leading through ambiguity and rapidly evolving competitive landscapes.
  • Experience building and leading high-performing marketing teams and developing future commercial leaders.
  • Significant United States healthcare professional marketing experience with integrated commercial strategy development.
  • Experience hiring, coaching, and developing high-performing teams.
  • Experience in rare disease, autoimmune or severe inflammatory disease, particularly rheumatology or gastroenterology.
  • Experience partnering with Medical Affairs, Market Access, Sales, and Global Marketing.
  • Strong strategic thinking and executive communication skills, including translating insights into clear decisions, performance narratives, and impactful commercial plans.
Responsibilities
  • Lead the integrated United States healthcare professional marketing strategy for UPLIZNA in IgG4-related disease, translating launch priorities into clear objectives, indication-specific strategies, and execution plans.
  • Be accountable for commercial performance by identifying growth opportunities, emerging risks, competitive dynamics, and actions needed to meet business objectives.
  • Shape annual brand planning, long-range planning, quarterly priorities, investment decisions, and performance management for the IgG4-related disease indication.
  • Lead market-shaping initiatives that build disease awareness and accelerate identification, diagnosis, referral, and treatment uptake across rheumatology, gastroenterology, nephrology, neurology, pathology, and radiology.
  • Guide healthcare professional and institutional segmentation, targeting, positioning, messaging, customer journeys, field engagement, and branded and unbranded promotional strategy.
  • Anticipate and address evolving treatment paradigms, clinical evidence, guidelines, access barriers, care coordination, and buy-and-bill considerations.
  • Serve as the United States commercial voice within the Global Brand Team and partner with Sales, Medical, Field Medical, Market Access, Patient Services, Analytics and Insights, Regulatory, Legal, Training, Operations, Omnichannel Marketing, Global Marketing, and other stakeholders to deliver commercial goals.
  • Integrate commercial strategy with evidence generation, medical education, access, patient support, and field execution; champion understanding of healthcare professionals, diagnostic stakeholders, patients, treatment journeys, and evolving customer needs.
  • Recruit, coach, and develop a high-performing marketing organization; manage agency partners, promotional investments, budgets, and external resources with financial stewardship and accountability.
  • Establish performance-management frameworks connecting strategy, execution, leading indicators, and business outcomes; monitor performance, lead timely course correction, and communicate risks and recommendations to senior leadership.
  • Foster strategic thinking, ownership, collaboration, agility, innovation, disciplined execution, and a constructive team culture.
Desired Qualifications
  • An MBA is preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.